Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607108 · ClinicalTrials.gov registry record · Phase 2
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
A Phase 2 study of Squamous Cell Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 7
- Study locations
NCT05607108 is a Phase 2 study of Squamous Cell Lung Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 13 participants, below the 44-participant average among 4 other Squamous Cell Lung Cancer trials with a reported enrollment target (70% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT05607108, a Phase 2 study of Squamous Cell Lung Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
Conditions Studied
Interventions
- DRUG ZEN003694
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05607108
The ClinicalTrials.gov registry entry for NCT05607108 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 44-participant average among 4 other Squamous Cell Lung Cancer trials with a reported enrollment target (70% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Squamous Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ZEN003694 is the first listed.
NCT05607108 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05607108 about?
NCT05607108 is a clinical study titled "A Study of ZEN003694 in People With Squamous Cell Lung Cancer". The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking ...
What is the current status of trial NCT05607108?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2022-11-01. Estimated completion is 2027-11.
What conditions does trial NCT05607108 study?
This clinical trial studies the following conditions: Squamous Cell Lung Cancer.
What interventions are being tested in trial NCT05607108?
The interventions under investigation include: ZEN003694 (DRUG).
Who is sponsoring clinical trial NCT05607108?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607108 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
ACTIVE NOT RECRUITING · NA
-
Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.